Alerta

EXOSOME ISOLATION METHOD

Resumen de: WO2026075627A1

Process of the invention, utilizes L-arginine-coated magnetic nanobeads for exosome isolation. pre-processing steps consisting of filtration and low-speed centrifugation enrich exosome- containing samples, allowing for more economical use of magnetic beads in subsequent stages compared to the initial sample volume.

SMAGP FUSION MOLECULES AND METHODS OF USE THEREOF

Resumen de: US20260098070A1

0000 Provided herein are fusion molecules comprising a SMAGP extracellular domain that can modulate leukocyte activity. Also provided are polynucleotides, vectors, and host cells encoding these fusion molecules, and methods of making and using these fusion molecules.

A MODIFIED PROTEIN SCAFFOLD AND USE THEREOF

Resumen de: US20260098080A1

0000 A protein comprising amino acid sequence of SEQ ID NO: 115, within which a segment of general formula Ih-mod GX<1>CX<1V>X<2>X<3>X<4>X<5 >is present where X<1 >is any of F, Y, L, P, Q, M, V, W, A, or T, X<1V >is R, or K, X<2 >is any of A, G, S, or T, X<3 >is any amino acid of the 17-set, where the 17-set comprises A, I, L, F, or Y, X<4 >is any of K, I, Q, R, H, S, F, M, N, L, or V, and X<5 >is any of R, V, I, K, M, Q, E, F, L, N, Y, D, S, H; and b) in position 34 of SEQ ID NO: 115 it contains an amino acid selected from the 34-set contains any amino acid of the 34-set, where the 34-set comprises Y, I, F, G, V and S, and use in pharmaceutical preparations, kits, screening procedures.

BIOMARKERS IN LONG-COVID-19

Resumen de: US20260098868A1

A method of diagnosing long-COVID-19 in a patient, the method comprising: (a) obtaining a test sample from the patient, (b) performing one or more assays configured to detect a level of one or more biomarkers in the test sample, (c) comparing the level of the one or more proteins in the test sample with a healthy control reference value of said one or more proteins, wherein a change in the level of the one or more biomarkers in the test sample relative to the healthy control reference value of said one or more proteins is indicative of long-COVID-19 diagnosis, wherein the one or more proteins are selected from Table 3.

INFLAMMATORY DISEASE GENE PANEL

Resumen de: US20260098305A1

Provided is a method of determining whether a patient has bladder cancer, colon cancer, or breast cancer. Also provided is a method of determining whether a patient has a chronic inflammatory disease. Additionally provided is a method of evaluating patient response to a treatment for a chronic inflammatory disease. Further provided is a method of developing a treatment for a chronic inflammatory disease in a patient.

METHOD OF DETERMINING THE HEALTH STATUS OF A DOG

Resumen de: AU2024370445A1

The present invention provides a method for determining a biological age, mortality risk and/or probability of a healthy lifespan of a dog; said method comprising: a) determining a biological age, mortality risk and/or probability of a healthy lifespan of the dog using the level of one or more biomarker(s) in one or more samples obtained from the dog, wherein the one or more biomarker(s) is selected from white blood cell count, serum albumin, serum alkaline phosphatase, serum creatine kinase, haemoglobin, haematocrit, mean corpuscular haemoglobin, serum glucose, mean red cell volume, serum globulin, serum calcium, platelet count, and/or red blood cell count; and b) determining a biological age, mortality risk and/or probability of a healthy lifespan for the dog using a DNA methylation profile from the dog.

METHODS FOR INHIBITING DIAZEPAM BINDING PROTEIN

Resumen de: US20260097094A1

0000 Autophagy is typically activated by starvation, allowing cells and organisms to mobilize their energy reserves. It is known that pharmacological modulation of autophagy represents a therapeutic potential. Here the inventors report that a protein that is released from cells in an unconventional, autophagy-dependent manner, namely, diazepam binding inhibitor (DBI), regulates autophagy. In particular, the inventors demonstrate that DBI inhibits autophagy and that the supply of recombinant DBI to mice enhanced glycolysis, enhanced lipogenesis, and inhibited fatty acid oxidation. The inventors show that neutralisation of DBI by a monoclonal antibody and an active immunization by means of an immunogenic DBI derivative eliciting autoantibodies induce autophagy and lead to metabolic changes that increase starvation-induced weight loss, reduce food intake upon refeeding, and reduce weight gain in response to hypercaloric diets. Accordingly, the present invention relates to methods and pharmaceutical compositions for modulating autophagy based on the modulation of the activity or expression of DBI.

TREATED DRIED BLOOD SAMPLE FOR DETECTION OF HEAVY METALS IN DRIED BLOOD

Resumen de: US20260098855A1

0000 The present invention provides methods, compositions, kits, and devices for detecting heavy metals in dried blood (e.g., dried blood spots). For example, the present invention provides: 1) dried blood spot paper that is detectably free of heavy metals and methods of preparing such paper using organic acid; 2) dried blood extraction solutions optimized for heavy metal detection (e.g., extraction solutions containing acetic acid and/or gold); 3) methods for estimating venous blood volume from dried blood mass; and 4) kits and kit components optimized for heavy metal detection in dried blood (e.g., kits with paper detectably free of heavy metals, heavy metal free skin wipes, metal free collection case, etc.).

COMPOSITIONS AND METHODS FOR MODULATING NEURAL ACTIVITY

Resumen de: WO2026076419A1

Provided herein are, inter alia, methods and compositions for transfecting a brain cell (e.g., neuron). The methods for transfecting a brain cell provided herein including embodiments thereof include, for example, transfecting the brain cell with a viral vector encoding a potassium-selective light-sensitive protein (e.g., kalium channelrhodopsin). Also provided herein are, inter alia, methods of modulating a neural network of brain cells (e.g., neurons) by activating a potassium-selective channelrhodopsin with light. The methods and compositions provided herein are, inter alia, useful for treating neurological or psychiatric diseases or disorders (e.g., epilepsies, Parkinson's disease, Alzheimer's, etc.).

A METHOD FOR CLASSIFYING A SUBJECT AS HIGH-RISK FOR NEUROLOGICAL OR PSYCHIATRIC DISORDER

Resumen de: WO2026074061A1

In the present invention provided is a method for classifying a subject as a high-risk for neurological or psychiatric disorder subject. The method is particularly useful when the neurological or psychiatric disorder is selected from the group containing schizophrenia, psychosis, mood disorder, depression (such as major depressive disorder), bipolar disorder, Alzheimer's disease, Parkinson disorder, and cognitive impairment. The present invention further relates to a biomarker kit comprising reagents for determining expression level of biomarkers for extracellular vesicles, brain-derived extracellular vesicles and biomarkers for mitochondrial and redox impairment, N-methyl-D-aspartate receptor pathway, and other pathways related to central nervous system disorders.

COMPOSITIONS AND METHODS FOR IN VIVO DETECTION, DIAGNOSIS AND TREATMENT OF A DISEASE OR A DISORDER

Resumen de: WO2026076310A1

The present disclosure relates to synthetic probes and methods of using the synthetic probes. The synthetic probes include a binding domain that specifically binds a target, a cleavable linker, and a reporter. Cleaving the linker releases the reporter after a sufficient time following administration of a cleaving agent allowing for collection of the released reporter in a sample from the subject. The synthetic probes and methods can be used to diagnose a disease or disorder in a subject having or suspected of having a disease or disorder and for treating a disease or disorder.

A field-effect transistor based biosensor having an electrode insulation layer.

Resumen de: KR20260047788A

본 발명은 전해질을 게이트 절연층으로 사용하는 트랜지스터 기반 바이오 센서에 있어서, 전극 표면에 자기조립 다층 분자막으로 이루어진 전극 절연층을 구비함으로써 전기 누전에 의한 전극의 단락을 방지하고 우수한 패시베이션 효과를 구현할 수 있고, 나아가 표적 물질을 정확하고 신속하게 검출할 수 있는 전극 절연층을 갖는 전계효과 트랜지스터 기반 바이오 센서에 관한 것이다.

A field-effect transistor based biosensor having an electrode insulation layer.

Resumen de: KR20260047787A

본 발명은 전해질을 게이트 절연층으로 사용하는 트랜지스터 기반 바이오 센서에 있어서, 전극 표면에 자기조립 다층 분자막으로 이루어진 전극 절연층을 구비함으로써 전기 누전에 의한 전극의 단락을 방지하고 우수한 패시베이션 효과를 구현할 수 있는 전극 절연층을 갖는 전계효과 트랜지스터 기반 바이오 센서에 관한 것이다.

DIAGNOSTIC METHODS FOR AMYLOIDOSIS AND RELATED DISORDERS

Resumen de: WO2026075851A1

The present invention provides novel non-invasive methods for detecting misfolded transthyretin (TTR) proteins, and for diagnosing and monitoring amyloidosis and related disorders.

NON-INVASIVE METHOD FOR DETERMINING RESPIRATORY GASES COMPRISING HYDROGEN SULPHIDE

Resumen de: EP4721657A1

Die vorliegende Erfindung betrifft ein nicht-invasives Verfahren zur Bestimmung von Atemgasen aufweisend Schwefelwasserstoff, insbesondere zur Verwendung in der Medizin, Diagnose, Prädiktion, Risikostratifizierung und Therapiesteuerung von Erkrankungen, insbesondere Darmerkrankungen an Probanden, wobei durch Bakterien gebildete Gase in dem Ausatemgas bestimmt werden, wobei der Schwefelwasserstoff nicht nachteilig abgebaut wird.

用于主动脉夹层检测的生物标志物及其应用

Resumen de: CN121802031A

0001 本发明公开了用于主动脉夹层检测的生物标志物及其应用，所述生物标志物为MDK、NTN1、CCL21、LIPC、DNASE1L3、TFPI2、CTSG、HAMP、CXCL14、PLA2G2A、SCUBE1、GZMK、HP1BP3、SRP14、TOP1中的一种或多种。所述生物标志物通过血浆蛋白组学对主动脉夹层患者血浆筛选而出，表现出较高的敏感性和特异性。本发明通过ELISA验证证明了所述生物标志物可作为主动脉夹层早期诊断性生物标志物，还可以作为评估AD患者疾病严重程度的指标之一，这为主动脉夹层临床早期诊断和远期预后评估，提供了新的方向。

基于氮化硅纳米孔和深度学习的生物标志蛋白检测系统

Resumen de: CN121805567A

0001 本发明公开了基于氮化硅纳米孔和深度学习的生物标志蛋白检测系统，涉及纳米孔蛋白检测技术领域，包括基于电导‑孔径公式计算实现孔径的控制；保留并表征结构蛋白在过孔过程中产生的电信号差异；完成生物标志蛋白检测。本发明实现了对结构高度相似的β‑淀粉样蛋白40与β‑淀粉样蛋白42的高精度、高稳定性区分；提升了分类准确率，整体方案兼具工艺可控性、信号解析深度与模型识别能力，为阿尔茨海默病等神经退行性疾病的早期诊断提供了可靠、可产业化的单分子检测技术路径。

预防和治疗阿尔茨海默病药物、靶点、药物筛选方法

Resumen de: CN121796373A

本发明属于生物医药领域，具体的，本发明涉及了预防和治疗阿尔茨海默病药物、靶点、药物筛选方法。本发明揭示了甲状腺激素T4在治疗神经病变中核心靶标蛋白碘化PP2A的作用，为开发预防和治疗神经退行相关疾病的新药物、监测相关药物治疗效果提供了技术基础。甲状腺激素T4可以作为改善受试者记忆与认知功能的药物；补充甲状腺激素T4还可以用于预防和治疗神经退行性相关疾病，为甲状腺激素T4提供了一种全新的医药用途。

一种复合蛋白及其制备方法和应用

Resumen de: CN121800903A

本发明公开了一种复合蛋白及其制备方法和应用，涉及生物领域。本发明开发了一种多磷酸化tau复合蛋白，其包括链霉亲和素以及与所述链霉亲和素相连的抗原A‑生物素A和抗原B‑生物素B，解决现有校准品与天然抗原表位的差异引发试剂批间差过大的问题，校准性能突破性提升，可适配化学发光、酶联免疫等多种检测平台，通用性强，具有重要的临床价值与行业意义。

检测MAPT蛋白S202和T205位点磷酸化水平的试剂在制备肾脏纤维化诊断产品中的应用

Resumen de: CN121805597A

0001 本发明公开检测MAPT蛋白S202和T205位点磷酸化水平的试剂在制备肾脏纤维化诊断产品中的应用，本发明首次将MAPT蛋白的功能研究从传统的肾小球足细胞领域拓展至肾小管上皮细胞及其纤维化病理过程，开辟了MAPT蛋白在肾脏疾病研究中的全新方向。不同于既往仅依赖整体基因敲除或过表达的笼统性研究手段，本发明利用位点特异性突变体实现了对MAPT关键磷酸化位点功能的精准解析。通过系统性功能判定实验，本发明揭示了一项具有重大理论意义的反直觉生物学规律：尽管S202和T205位点磷酸化显著驱动肾小管上皮细胞纤维化进程，但模拟该位点去磷酸化状态（S202A/T205A突变体）却无法改善纤维化表型。

AAV METHODS OF AAV THERAPY

Resumen de: WO2019246237A1

This disclosure provides methods for identifying a subject suitable for an adeno associated virus (AAV) therapy. In some embodiments, the method comprises measuring a titer of an antibody or antigen-binding portion thereof that specifically binds to an AAV ("anti-AAV antibody") in a biological sample obtained from the subject using an enzyme-linked immunosorbent assay (ELISA).

一种基于RT-QuIC技术的帕金森病辅助诊断试剂盒及其应用

Resumen de: CN121805593A

0001 本发明提供一种基于RT‑QuIC技术的帕金森病辅助诊断试剂盒及其应用，属于检测试剂盒技术领域。本发明提供的试剂盒具有显著的微创性与高患者依从性，仅需采集微量皮肤组织即可完成检测，避免了腰椎穿刺或脑组织活检的风险与痛苦。该试剂盒检测性能优异，能够实现对帕金森病早期病理的高度敏感与特异的识别，且检测流程快捷，可在较短时间内完成批量样本分析，有力支持临床的快速诊断与筛查需求。同时，其整体成本显著低于影像学等现有方法，为帕金森病的早期发现、临床辅助诊断及治疗效果观察提供了便捷、可靠且经济的分子检测手段，对提升该类神经退行性疾病的整体诊疗水平具有积极意义。

ＹａｘＡＢナノポア、それを含むナノポアシステム、およびその活用

Resumen de: EP1000000A1

The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.

线粒体Rab32在制备用于治疗慢性睡眠剥夺药物中的应用及其研究方法

Resumen de: CN121775117A

0001 本发明公开了线粒体Rab32在制备用于治疗慢性睡眠剥夺药物中的应用及其研究方法，属于生物医药技术领域。本发明通过建立慢性睡眠剥夺小鼠模型，研究线粒体Rab32与SD小鼠体内蛋白变化的关系，结果表明，线粒体Rab32通过锚定细胞内Sptan1，参与细胞骨架蛋白功能调控，参与神经元的突触再生，由此可得，Rab32是介导SD小鼠神经元突触再生、调节突触可塑性和认知功能障碍的关键分子，该研究结果可能为今后SD相关认知功能障碍的治疗提供新的靶点。

SEMA3G抗原结合蛋白及其用途

Nº publicación: CN121779558A 03/04/2026

Solicitante:

上海柏全生物科技有限公司复旦大学

Resumen de: CN121779558A

0001 本申请涉及生物医药领域，具体涉及SEMA3G抗原结合蛋白及其用途。本申请提供一种分离的抗原结合蛋白，所述抗原结合蛋白结合SEMA3G蛋白，所述抗原结合蛋白包括重链可变区和轻链可变区；所述重链可变区包括如SEQ ID NO.3、11、19任一项所示的HCDR1，如SEQ ID NO.4、12、20任一项所示的HCDR2，如SEQ ID NO.5、13、21任一项所示的HCDR3；所述轻链可变区包括如SEQ ID NO.6、14、22任一项所示的LCDR1，如SEQ ID NO.7、15、23任一项所示的LCDR2，如SEQ ID NO.8、16、24任一项所示的LCDR3；本申请的抗原结合蛋白能够以高亲和力结合上述靶蛋白并且中和其对T细胞功能的抑制活性，从而达到解除肿瘤细胞免疫逃逸功能的作用，促进免疫细胞在体内外对肿瘤细胞的杀伤，可用于制备调节免疫反应或具有抗肿瘤作用的药物。